News - Cardio-vascular, Licensing


Current filters:


Popular Filters

1 to 25 of 59 results

Ligand licenses five programs to Viking Therapeutics


US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

Cardiome out-licenses Aggrastat in select European markets


Canada-based Cardiome Pharma has signed an agreement with AOP Orphan Pharmaceuticals, headquartered in…

AggrastatAOP OrphanAustriaBrinavessCardio-vascularCardiome PharmaHungaryLicensingPharmaceutical

Ligand signs dyslipidemia related diseases accord with AstraZeneca unit


US drugmaker Ligand Pharmaceuticals has entered into a licensing agreement and research collaboration…

AstraZenecaCardio-vascularLicensingLigand PharmaceuticalsOmthera PharmaceuticalsPharmaceuticalResearch

AstraZeneca signs deals for antibiotic and cardiovascular research

AstraZeneca signs deals for antibiotic and cardiovascular research


Anglo-Swedish drug major AstraZeneca has entered into further collaborations to expand its research base,…

Antibiotics and Infectious diseasesAstraZenecaCardio-vascularFOB SynthesisLicensingPharmaceuticalResearch

Capricor Therapeutics and Janssen collaborate on cell therapy program

Capricor Therapeutics and Janssen collaborate on cell therapy program


California, USA-based Capricor Therapeutics says it has executed a collaboration agreement and exclusive…

BiotechnologyCAP-1002Capricor TherapeuticsCardio-vascularJanssen BiotechJohnson & JohnsonLicensing

AstraZeneca and Shionogi settle Crestor arbitration

AstraZeneca and Shionogi settle Crestor arbitration


Anglo-Swedish drug major AstraZeneca revealed yesterday (December 26) the full resolution of arbitration…


Oxygen Biotherapeutics signs agreement to acquire Phase III cardiac drug from Phyxius Pharma


US drug developer Oxygen Biotherapeutics has signed a Definitive Agreement to acquire certain assets…

Cardio-vascularLevosimendanLicensingMergers & AcquisitionsNorth AmericaOxygen BiotherapeuticsPharmaceutical

Xention and Servier sign up for cardiovascular collaboration

Xention and Servier sign up for cardiovascular collaboration


Xention and Servier have entered into a multi-year agreement for the development and commercialization…


Cardiome in deal for commercialization of Brinavess in Israel


Canada-based Cardiome Pharma (TSX: COM) has entered into an agreement with Tzamal Medical to sell and…

BrinavessCardio-vascularCardiome PharmaLicensingPharmaceuticalRest of the WorldTzamal Medical

Takeda out-licenses Edarbi and Edarbyclor


Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered into a license, development and…

Arbor PharmaceuticalsCardio-vascularEdarbiEdarbyclorLicensingNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Sanofi US in deal to commercialize PA8140/PA32540


The US subsidiary of French drug major Sanofi (Euronext: SAN) has entered into a deal with US drugmaker…

AspirinCardio-vascularGastro-intestinalsLicensingNorth AmericaOmeprazolePharmaceuticalPozenSanofi

Amgen's US deal with Servier cleared


USA-based Amgen (Nasdaq: AMGN), the world's leading independent biotech firm, and privately-held French…

AmgenBiotechnologyCardio-vascularLicensingNorth AmericaPharmaceuticalProcoralanServier

Forest agrees another license deal for Bystolic


US drugmaker Forest Laboratories (NYSE:FRX) and Forest Laboratories Holdings have reached a settlement…

Amerigen PharmaceuticalsBystolicCardio-vascularForest LaboratoriesGenericsLicensingNorth AmericaPharmaceutical

Amgen gains rights to Servier's heart drugs ivabradine and S38844


USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has entered a new collaboration…

AmgenBiotechnologyCardio-vascularEuropeivabradineLicensingNorth Americaomecamtiv mecarbilPharmaceuticalS38844Servier

XOMA transfers perindopril franchise rights to Symplmed


California, USA-based XOMA Corp (Nasdaq: XOMA) says it has transferred US development and commercialization…

Cardio-vascularLicensingMergers & AcquisitionsperindoprilPharmaceuticalServierSymplmedXOMA Corp

Pharming and SIPI collaboration includes Ruconest marketing in China


Dutch biotech company Pharming Group (NYSE Euronext: PHARM) and Shanghai Institute of Pharmaceutical…

Asia-PacificBiotechnologyCardio-vascularLicensingPharmaceuticalPharmingResearchRuconestSinopharm Group

Cardiome gains European MA rights for Brinavess from Merck & Co


Canada-based Cardiome Pharma (TSX: COM) has announced adoption of the decision by the European Commission…

BrinavessCardio-vascularCardiome PharmaEuropeLicensingMerck & CoPharmaceuticalRegulation

SciClone and Taiwan Liposome link up on ProFlow for China


USA-based SciClone Pharmaceuticals (Nasdaq: SCLN) yesterday (June 25) has announced an agreement with…

Asia-PacificCardio-vascularLicensingPharmaceuticalProFlowSciClone PharmaTaiwan Liposome

Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis


Sweden-based Athera Biotechnologies, which is 65% owned by Karolinska Development, has entered into an…

Athera BiotechnologiesBiotechnologyBoehringer IngelheimCardio-vascularKarolinska DevelopmentLicensing

Amgen and Cytokinetics expand omecamtiv mecarbil accord


USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech company, has expanded its strategic…

AmgenAsia-PacificBiotechnologyCardio-vascularCytokineticsLicensingomecamtiv mecarbil

Abcam in deal with Pfizer to supply compounds to researchers


UK-based Abcam (AIM: ABC), a producer and distributor of protein research tools, has entered into a license…


RedHill Biopharma views regulatory pathway for RHB-101 in CHF and hypertension


Emerging Israeli biopharma company RedHill Biopharma (TASE: RDHL) says that it recently concluded a positive…

BiotechnologyCardio-vascularCarvedilolLicensingPharmaceuticalRedHill BiopharmaRegulationResearchRHB-101

SciClone gains China rights to Zensun's Neucardin


USA-based SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the Company has entered into an…

Asia-PacificCardio-vascularLicensingNeucardinPharmaceuticalSciClone PharmaZensun

1 to 25 of 59 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top